Aeterna Zentaris preclinical data

In a mouse xenograft model, AEZS-126 showed antitumor activity at 30 mg/kg daily. Oral bioavailability was about 60%. The phosphoinositide 3-kinase (PI3K) inhibitor acts as an ATP-competitive compoun...